Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX)
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2013
At a glance
- Drugs Octreotide (Primary) ; Doxorubicin
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 18 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Sep 2005 New trial record.